Vorapaxar


FDA Advisory Panel Votes In Favor Of Approval For Merck's Vorapaxar

FDA Advisory Panel Votes In Favor Of Approval For Merck's Vorapaxar

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-1 in favor of approval for vorapaxar, Merck's novel thromb...

Jan 15 2014, 5:21pm CST

I4U news

Merck's Vorapaxar Gets Positive FDA Review

A few years ago a novel antiplatelet agent from Merck seemed all but dead. Vorapaxar, a thrombin receptor antagonist, was widel...

Jan 13 2014, 2:31pm CST